Global Bladder Cancer Market

Global Bladder Cancer Market Size, Trends & Analysis - Forecasts to 2026 By Type (Transitional Cell, Invasive, Superficial, Squamous Cell, Adenocarcinoma, Others), By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Others), By Diagnosis (Urine Lab Tests [Urine Cytology, Urine Culture, Urine Tumor Marker Test], Cystoscopy, Biopsy, Imaging Test [Intravenous Pyelogram (IVP), Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI) Scan, Ultrasound]), Competitive Landscape, Company Market Share Analysis, and Competitor Analysis; By Region (North America, Europe, Asia Pacific, MEA, and CSA); End-User Landscape, Company Market Share Analysis & Competitor Analysis

Category Healthcare

Format

This report was recently updated on May 9 2024 with the latest and most recent market numbers

Bladder Cancer Market: Insights

The bladder cancer market is estimated to be valued at USD 3.45 billion in 2021 and is projected to reach USD 4.24 billion by 2026 at a CAGR of 4.19%. The global market is spurred by rising cancer prevalence, which has resulted in drug development and technological advances. This cancer is more likely in people over the age of 50. As a result, the bladder cancer market size will increase due to the growing elderly demographic. Moreover, the global market is predicted to be propelled by government programs, increased understanding regarding cancer and viable therapies, and advanced health care services with rising healthcare spending.

Nevertheless, because cancer is an inconspicuous condition in its early stages, it necessitates a proper diagnosis. The market's expansion could be hampered by inaccuracies and high costs of diagnostics. The slow growth of the market is due to an increase in the utilization of generic pharmaceuticals and an increase in patent maturities.

An expanding core patient demographic as well as the authorization and introduction of novel branded medicines with various MOAs, will propel the market to phenomenal ascent. In particular, throughout the forecast period, the license extension of commercially available medicines such as PD-1/PD-L1 checkpoint inhibitors in conjunction with chemotherapies or even other immuno-oncology drugs will drive market development. In this cancer, PD-1/PD-L1 checkpoint inhibitors are generally utilized and they are predicted to see increased acceptance and employment in various avenues of therapy around the world, particularly in countries where unfulfilled demand is greatest.

PD-1/PD-L1 inhibitors, as monotherapy or in conjunction, are likely to generate considerable profitability owing to superior price and therapeutic advantages in BCG-relapsed and recalcitrant patients, as well as patients who are disqualified for platinum-based therapy. Notable market catalysts include PD-1/PD-L1 inhibitors and the introduction of innovative medications such as Vicinium, N-803, and Instiladrin for non-muscle invasive cancer patients. In additament, investigating tailored therapy approaches in collaboration with immune checkpoint inhibitors will help to improve drug acceptance amongst patients with different types of this cancer.

global bladder cancer market

Bladder Cancer Market: By Type

Based on type, the market is segmented into transitional cells, invasive, superficial, squamous cells, adenocarcinoma, and others. The superficial bladder cancer segment is foreseen to hold the largest market share. In recent years, the incidence of cancer and mortality attributable to cancer has been modestly decreasing in women. Prevalence levels in men have been declining, while mortality rates have remained steady.

Bladder Cancer Market: By Therapy

Based on therapy, the market is classified into chemotherapy, immunotherapy, radiation therapy, surgery, and others. The chemotherapy segment is foreseen to hold the largest market share. Chemotherapeutics pertains to the use of medications to treat a specific ailment. Chemotherapy is the first line of defense against cancer. The medicine is given either intravenously or topically to the urinary bladder to treat this cancer. Chemotherapy and BCG immunotherapy are commonly used to treat non-muscle invasive bladder cancer (NMIBC). There has been little progress in cancer chemotherapy drugs. Additionally, the prevalence of cancer is significant in the general demographic, which is likely to propel the market forward throughout the forecast period.

Bladder Cancer Market: By Diagnosis

Based on the diagnosis, the market is segmented into urine lab tests, cystoscopy, biopsy, and imaging tests. Urine lab tests can be further divided into urinalysis, urine cytology, urine culture, and urine tumor marker tests. The imaging tests segment can be further divided into intravenous pyelogram (IVP), computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, and ultrasound. During the forecast period, the cystoscopy segment is expected to hold the major market share. A cystoscope is a working endoscope that is inserted into the bladder via the urethra and allows immediate ocular examination of the urothelium. Since it is low-risk and permits the urologist to obtain biopsy samples and amputate papillary tumors in a single session, cystoscopy is the principal method for the diagnosis of this cancer.

asia pacific bladder cancer market

Bladder Cancer Market: By Region

North America controls a large portion of the global market. The ascent in cancer prevalence new health care alternatives, sophisticated health care architecture and increased worry concerning bladder diseases are all contributing to the area's growth. Because of expanding research and development and well-established, sophisticated healthcare in the area, North America has the highest share. Furthermore, the inclusion of a significant multitude of therapeutics and biopharmaceutical businesses contributes to the cancer therapies and diagnostics market's large size and rapid growth. North America does have the highest frequency of implementation of novel diagnostics techniques that are commercially available.

Europe holds the second-largest share of the global market. The market's expansion can be due to well-developed healthcare architecture high healthcare spending and rising cancer occurrence and severity in several Eurozone countries. Furthermore, the significant frequency of cancer in the area, as well as increasing awareness campaigns, are driving market expansion. Moderately active habits in the nation, including smoking, drug use, and liquor drinking, are key contributors to the rising prevalence of this cancer amongst males and females. Federal programs, initiatives, and financing for cancer-related projects all contribute to the area's market prosperity.

Throughout the forecast period, the Asia-Pacific market is expected to expand at the highest CAGR. One of the key variables contributing to the rising population of cancer patients in Asian countries is the soaring proportion of smokers. Owing to evolving lifestyles and altering tendencies regarding smoking and nicotine usage, the percentage of smokers in the mature demographic of the area is increasing dramatically. Radiation exposure, ingesting or being susceptible to dangerous substances, age, and other variables are all thought to play a role in the development of this cancer. Owing to the deterioration of immune cells opposing cancerous cells in the bladder, aging is regarded as one of the key reasons contributing to this cancer. Economies in the Asia region, including Japan and China, are rapidly aging populations. As a result, the Asia-Pacific area is more susceptible to this cancer than most other areas.

Bladder Cancer Market Share and Competitor Analysis

Pfizer Inc., Accord Healthcare, Merck and Co. Inc., Bedford La, Sanofi S.A., Novartis AG, Pfizer Inc., GlaxoSmithKline pic, Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Allergan Inc., Johnson & Johnson, Bedford Lab, and Celgene Corporation, among others, are the key players in the market.

Please note: This is not an exhaustive list of companies profiled in the report.

Chapter 1 Methodology

1.1 Market Scope & Definitions

1.2 Estimates & Forecast Calculation

1.3 Historical Data Overview and Validation

1.4 Data Sources

1.4.1 Secondary

1.4.2 Primary

Chapter 2 Report Outlook

2.1 Bladder Cancer Industry Overview, 2016-2026

2.1.1 Industry Overview

2.1.2 Type Overview

2.1.3 Therapy Overview

2.1.4 Diagnosis Overview

2.1.5 Regional Overview

Chapter 3 Bladder Cancer Market Trends

3.1 Market Segmentation

3.2 Industry Background, 2016-2026

3.3 Market Key Trends

3.3.1 Positive Trends

3.3.1.1 Rising Healthcare Spending

3.3.1.2 Expanding Core Patient Demographics

3.3.2 Industry Challenges

3.3.2.1 High Costs Associated with Diagnosis

3.4 Prospective Growth Scenario

3.4.1 Type Growth Scenario

3.4.2 Therapy Growth Scenario

3.4.3 Diagnosis Growth Scenario

3.5 COVID-19 Influence over Industry Growth

3.6 Porter’s Analysis

3.7 PESTEL Analysis

3.8 Value Chain & Supply Chain Analysis

3.9 Regulatory Framework

3.9.1 North America

3.9.2 Europe

3.9.3 APAC

3.9.4 LATAM

3.9.5 MEA

3.10 Technology Overview

3.11 Market Share Analysis, 2020

3.11.1 Company Positioning Overview, 2020

Chapter 4 Bladder Cancer Market, By Type

4.1 Type Outlook

4.2 Transitional Cell

4.2.1 Market Size, By Region, 2016-2026 (USD Million)

4.3 Invasive

4.3.1 Market Size, By Region, 2016-2026 (USD Million)

4.4 Squamous Cell

4.4.1 Market Size, By Region, 2016-2026 (USD Million)

4.5 Adenocarcinoma

4.5.1 Market Size, By Region, 2016-2026 (USD Million)

4.6 Superficial

4.6.1 Market Size, By Region, 2016-2026 (USD Million)

4.7 Others

4.7.1 Market Size, By Region, 2016-2026 (USD Million)

Chapter 5 Bladder Cancer Market, By Therapy

5.1 Therapy Outlook

5.2 Chemotherapy

5.2.1 Market Size, By Region, 2016-2026 (USD Million)

5.3 Immunotherapy

5.3.1 Market Size, By Region, 2016-2026 (USD Million)

5.4 Radiation Therapy

5.4.1 Market Size, By Region, 2016-2026 (USD Million)

5.5 Surgery

5.5.1 Market Size, By Region, 2016-2026 (USD Million)

5.6 Others

5.6.1 Market Size, By Region, 2016-2026 (USD Million)

Chapter 6 Bladder Cancer Market, by Diagnosis

6.1 Diagnosis Outlook

6.2 Urine Lab Tests

6.2.1 Market Size, By Region, 2016-2026 (USD Million)

6.2.2 Urine Cytology, Market Size, By Region, 2016-2026 (USD Million)

6.2.3 Urine Culture, Market Size, By Region, 2016-2026 (USD Million)

6.2.4 Urine Tumor Marker Test, Market Size, By Region, 2016-2026 (USD Million)

6.3 Cystoscopy

6.3.1 Market Size, By Region, 2016-2026 (USD Million)

6.4 Biopsy

6.4.1 Market Size, By Region, 2016-2026 (USD Million)

6.5 Imaging Test

6.5.1 Market Size, By Region, 2016-2026 (USD Million)

6.5.2 Intravenous Pyelogram (IVP), Market Size, By Region, 2016-2026 (USD Million)

6.5.3 Computed Tomography (CT) Scan, Market Size, By Region, 2016-2026 (USD Million)

6.5.4 Magnetic Resonance Imaging (MRI) Scan, Market Size, By Region, 2016-2026 (USD Million)

6.5.5 Ultrasound, Market Size, By Region, 2016-2026 (USD Million)

Chapter 7 Bladder Cancer Market, By Region

7.1 Regional outlook

7.2 North America

7.2.1 Market Size, By Country 2016-2026 (USD Million)

7.2.2 Market Size, By Type, 2016-2026 (USD Million)

7.2.3 Market Size, By Therapy, 2016-2026 (USD Million)

7.2.4 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.2.5 U.S.

7.2.5.1 Market Size, By Type, 2016-2026 (USD Million)

7.2.5.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.2.5.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.2.6 Canada

7.2.6.1 Market Size, By Type, 2016-2026 (USD Million)

7.2.6.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.2.6.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.3 Europe

7.3.1 Market Size, By Country 2016-2026 (USD Million)

7.3.2 Market Size, By Type, 2016-2026 (USD Million)

7.3.3 Market Size, By Therapy 2016-2026 (USD Million)

7.3.4 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.3.5 Germany

7.3.5.1 Market Size, By Type, 2016-2026 (USD Million)

7.3.5.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.3.5.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.3.6 UK

7.3.6.1 Market Size, By Type, 2016-2026 (USD Million)

7.3.6.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.3.6.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.3.7 France

7.3.7.1 Market Size, By Type, 2016-2026 (USD Million)

7.3.7.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.3.7.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.3.8 Italy

7.3.8.1 Market Size, By Type, 2016-2026 (USD Million)

7.3.8.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.3.8.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.3.9 Spain

7.3.9.1 Market Size, By Type, 2016-2026 (USD Million)

7.3.9.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.3.9.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.3.10 Russia

7.3.10.1 Market Size, By Type, 2016-2026 (USD Million)

7.3.10.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.3.10.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.4 Asia Pacific

7.4.1 Market Size, By Country,2016-2026 (USD Million)

7.4.2 Market Size, By Type, 2016-2026 (USD Million)

7.4.3 Market Size, By Therapy, 2016-2026 (USD Million)

7.4.4 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.4.5 China

7.4.5.1 Market Size, By Type, 2016-2026 (USD Million)

7.4.5.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.4.5.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.4.6 India

7.4.6.1 Market Size, By Type, 2016-2026 (USD Million)

7.4.6.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.4.6.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.4.7 Japan

7.4.7.1 Market Size, By Type, 2016-2026 (USD Million)

7.4.7.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.4.7.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.4.8 Australia

7.4.8.1 Market Size, By Type, 2016-2026 (USD Million)

7.4.8.2 Market size, By Therapy, 2016-2026 (USD Million)

7.4.8.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.4.9 South Korea

7.4.9.1 Market Size, By Type, 2016-2026 (USD Million)

7.4.9.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.4.9.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.6.5 Latin America

7.5.1 Market Size, By Country 2016-2026 (USD Million)

7.5.2 Market Size, By Type, 2016-2026 (USD Million)

7.5.3 Market Size, By Therapy, 2016-2026 (USD Million)

7.5.4 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.5.5 Brazil

7.5.5.1 Market Size, By Type, 2016-2026 (USD Million)

7.5.5.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.5.5.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.5.6 Mexico

7.5.6.1 Market Size, By Type, 2016-2026 (USD Million)

7.5.6.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.5.6.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.5.7 Argentina

7.5.7.1 Market Size, By Type, 2016-2026 (USD Million)

7.5.7.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.5.7.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.6 MEA

7.6.1 Market Size, By Country 2016-2026 (USD Million)

7.6.2 Market Size, By Type, 2016-2026 (USD Million)

7.6.3 Market Size, By Therapy, 2016-2026 (USD Million)

7.6.4 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.6.5 Saudi Arabia

7.6.5.1 Market Size, By Type, 2016-2026 (USD Million)

7.6.5.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.6.5.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.6.6 UAE

7.6.6.1 Market Size, By Type, 2016-2026 (USD Million)

7.6.6.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.6.6.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

7.6.7 South Africa

7.6.7.1 Market Size, By Type, 2016-2026 (USD Million)

7.6.7.2 Market Size, By Therapy, 2016-2026 (USD Million)

7.6.7.3 Market Size, By Diagnosis, 2016-2026 (USD Million)

Chapter 8 Company Landscape

8.1 Competitive Analysis, 2020

8.2 Pfizer Inc.

8.2.1 Company Overview

8.2.2 Financial Analysis

8.2.3 Strategic Positioning

8.2.4 Info Graphic Analysis

8.3 Accord Healthcare

8.3.1 Company Overview

8.3.2 Financial Analysis

8.3.3 Strategic Positioning

8.3.4 Info Graphic Analysis

8.4 Merck and Co. Inc.

8.4.1 Company Overview

8.4.2 Financial Analysis

8.4.3 Strategic Positioning

8.4.4 Info Graphic Analysis

8.5 Bedford La

8.5.1 Company Overview

8.5.2 Financial Analysis

8.5.3 Strategic Positioning

8.5.4 Info Graphic Analysis

8.6 Sanofi S.A.

8.6.1 Company Overview

8.6.2 Financial Analysis

8.6.3 Strategic Positioning

8.6.4 Info Graphic Analysis

8.7 Novartis AG

8.7.1 Company Overview

8.7.2 Financial Analysis

8.7.3 Strategic Positioning

8.7.4 Info Graphic Analysis

8.8 Pfizer Inc.

8.8.1 Company Overview

8.8.2 Financial Analysis

8.8.3 Strategic Positioning

8.8.4 Info Graphic Analysis

8.9 GlaxoSmithKline pic

8.9.1 Company Overview

8.9.2 Financial Analysis

8.9.3 Strategic Positioning

8.9.4 Info Graphic Analysis

8.10 Eli Lilly and Company

8.10.1 Company Overview

8.10.2 Financial Analysis

8.10.3 Strategic Positioning

8.10.4 Info Graphic Analysis

8.11 AstraZeneca plc

8.11.1 Company Overview

8.11.2 Financial Analysis

8.11.3 Strategic Positioning

8.11.4 Info Graphic Analysis

8.12 Bristol-Myers Squibb

8.12.1 Company Overview

8.12.2 Financial Analysis

8.12.3 Strategic Positioning

8.12.4 Info Graphic Analysis

8.13 F. Hoffmann-La Roche Ltd.

8.13.1 Company Overview

8.13.2 Financial Analysis

8.13.3 Strategic Positioning

8.13.4 Info Graphic Analysis

8.14 Allergan Inc.

8.14.1 Company Overview

8.14.2 Financial Analysis

8.14.3 Strategic Positioning

8.14.4 Info Graphic Analysis

8.15 Johnson & Johnson

8.15.1 Company Overview

8.15.2 Financial Analysis

8.15.3 Strategic Positioning

8.15.4 Info Graphic Analysis

8.16 Bedford Lab

8.16.1 Company Overview

8.16.2 Financial Analysis

8.16.3 Strategic Positioning

8.16.4 Info Graphic Analysis

8.17 Celgene Corporation

8.17.1 Company Overview

8.17.2 Financial Analysis

8.17.3 Strategic Positioning

8.17.4 Info Graphic Analysis

8.18 Other Companies

8.18.1 Company Overview

8.18.2 Financial Analysis

8.18.3 Strategic Positioning

8.18.4 Info Graphic Analysis

The Global Bladder Cancer Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Bladder Cancer Market.

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe. Privacy

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

What is the projected market size of the global bladder cancer market?

The global bladder cancer market size is projected to grow from USD 3.45 billion in 2021 to USD 4.24 billion by 2026, at a CAGR of 4.19% during the forecast period.

Who are the major vendors in the bladder cancer market?

Key and innovative vendors in the bladder cancer market include Pfizer Inc., Accord Healthcare, Merck and Co. Inc., Bedford La, Sanofi S.A., Novartis AG, Pfizer Inc., GlaxoSmithKline pic, Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Allergan Inc., Johnson & Johnson, Bedford Lab, and Celgene Corporation.

Which region has the highest market share in the bladder cancer market?

North America is estimated to hold the highest market share in the bladder cancer market.

What is the Covid-19 impact on future bladder cancer manufacturers?

Globally, Covid-19 impact on the future bladder cancer market will be quite significant for the manufacturers. North America would be leading because of the inclusion of a significant multitude of therapeutics and biopharmaceutical businesses. Europe holds the second-largest share of the global market due to well-developed healthcare architecture and high healthcare spending. Subsequently, the Asia Pacific market will be growing the fastest because of the evolving lifestyles and altering tendencies regarding smoking and nicotine usage.

What are the major drivers in the bladder cancer market?

The major driving factors for the bladder cancer market include the rising cancer prevalence; favorable government programs; increasing understanding regarding cancer and viable therapies; advanced health care services with rising healthcare spending; rising level of authorization and introduction of novel branded medicines with various MOAs.